Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | PAM | P19021 | 2/20 | 0.57 |
| ▸ | CES2 | O00748 | 3/20 | 0.56 |
| ▸ | CES1 | P23141 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 6/20 | 0.54 |
| ▸ | PPARD | Q03181 | 6/20 | 0.54 |
| ▸ | PPARA | Q07869 | 6/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5970488 | 1.00 | DGKA (0.64) | DGKALMNAALDH1A1PAMCES2 | |
| SCHEMBL7156970 | 1.00 | DGKA (0.64) | DGKALMNAALDH1A1PAMCES2 | |
| SCHEMBL27915729 | 1.00 | DGKA (0.64) | DGKALMNAALDH1A1PAMCES2 | |
| SCHEMBL15528070 | 1.00 | DGKA (0.64) | DGKALMNAALDH1A1PAMCES2 | |
| SCHEMBL8105373 | 1.00 | DGKA (0.64) | DGKALMNAALDH1A1PAMCES2 | |
| SCHEMBL15528012 | 1.00 | DGKA (0.64) | DGKALMNAALDH1A1PAMCES2 | |
| SCHEMBL15527948 | 1.00 | DGKA (0.64) | DGKALMNAALDH1A1PAMCES2 | |
| SCHEMBL152597 | 0.97 | DGKA (0.67) | DGKALMNAALDH1A1PAMCES2 | |
| SCHEMBL8584840 | 0.97 | DGKA (0.67) | DGKALMNAALDH1A1PAMCES2 | |
| SCHEMBL1696127 | 0.97 | DGKA (0.67) | DGKALMNAALDH1A1PAMCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 571 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980319-B2 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans | MALLINCKRODT LLC (US) | 2015-03-17 | — | — | US | claimed |
| US-20140086987-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | MALLINCKRODT LLC (US) | 2014-03-27 | — | — | US | claimed |
| US-8597681-B2 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans | MALLINCKRODT LLC (US) | 2013-12-03 | — | — | US | claimed |
| WO-2004098562-A2 | CONTROLLED RELEASE SOLID DOSAGE NIFEDIPINE FORMULATIONS | NOVEON IP HOLDINGS CORP. (US) | 2004-11-18 | — | — | WO | claimed |
| US-20040219210-A1 | Controlled release solid dosage nifedipine formulations | LUBRIZOL ADVANCED MATERIALS, INC. | 2004-11-04 | — | — | US | claimed |
| US-5840329-A | GROUPS OF PARTICLES HAVING DISTINCT PATTERN OF DRUG RELEASE BASED ON COMBINATION OF CONTROLLED RELEASE LAYERS, SWELLING AGENTS AND COATINGS; CONTROLLED RELEASE LAYER OF SLIGHTLY CROSSLINKED POLYACRYLIC ACID AND WATER SOLUBLE POLYMER | BIOADVANCES LLC (US) | 1998-11-24 | — | — | US | claimed |
| WO-1998051287-A1 | PULSATILE DRUG DELIVERY SYSTEM | BAI JANE PEI FAN (US) | 1998-11-19 | — | — | WO | claimed |
| US-4058122-A | Osmotic system with laminated wall formed of different materials | ALZA CORPORATION (US) | 1977-11-15 | — | — | US | claimed |
| US-20240156811-A1 | COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-16 | — | — | US | disclosed |
| US-11707451-B2 | Pharmaceutical composition for modified release | ASTELLAS PHARMA INC. (JP) | 2023-07-25 | — | — | US | disclosed |
| EP-4023223-A1 | COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-07-06 | — | — | EP | disclosed |
| US-20220000861-A1 | COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-01-06 | — | — | US | disclosed |
| US-20210085654-A1 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE | ASTELLAS PHARMA INC. (JP) | 2021-03-25 | — | — | US | disclosed |
| CN-108042808-B | Combination comprising brexpiprazole or salt thereof and a second drug for the treatment of central system diseases | 大塚制药株式会社 | 2021-02-09 | — | — | CN | disclosed |
| US-4160020-A | CELLULOSE ESTERS, CELLULOSE ETHERS | ALZA CORPORATION (US) | 1979-07-03 | — | — | US | disclosed |
| US-4116241-A | FOR CONTROLLED ORAL ADMINISTRATION OF DRUG | ALZA CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4077407-A | POLYSACCHARIDES | ALZA CORPORATION (US) | 1978-03-07 | — | — | US | disclosed |
| US-4058122-A | Osmotic system with laminated wall formed of different materials | ALZA CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
| US-4014334-A | Laminated osmotic system for dispensing beneficial agent | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-4008719-A | Osmotic system having laminar arrangement for programming delivery of active agent | ALZA CORPORATION (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707451-B2 | Pharmaceutical composition for modified release | SLC6A19, AASDHPPT, SLC6A15 | DGKA 4573/4885LMNA 4186/4885ALDH1A1 874/4885 |
| US-20140086987-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | DGKA 4699/4885LMNA 520/4885ALDH1A1 3382/4885 |
| US-20210085654-A1 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE | SLC6A19, AASDHPPT, SLC6A15 | DGKA 4573/4885LMNA 4186/4885ALDH1A1 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.